Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis

2024/10/18 by Ashwin N. Ananthakrishnan, M. Hassan Murad, Frank I. Scott +5 · 25 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Inflammatory Bowel Disease #Rheumatoid Arthritis Research and Therapies #Microscopic Colitis

paper · pdf · doi:10.1053/j.gastro.2024.07.046

Citations

• The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
• AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis
• Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis
• Incidence, Prevalence, and Racial and Ethnic Distribution of Inflammatory Bowel Disease in the United States

Cited by

• Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Crohn’s Disease: 2025 AGA Evidence Synthesis
• Network Meta‐Analysis: Efficacy of Biological Therapies and Small Molecules as Maintenance Therapy in Ulcerative Colitis
• Positioning and sequencing of advanced therapies in inflammatory bowel disease: A guide for clinical practice
• Efficacy and Safety of Janus Kinase-Inhibitors in Ulcerative Colitis. [europepmc]
• Role of Mirikizumab in the Treatment of Inflammatory Bowel Disease-From Bench to Bedside. [europepmc]
• IL-23p19 Antagonists vs Ustekinumab for Treatment of Crohn's Disease: A Meta-Analysis of Randomized Controlled Trials. [europepmc]
• Optimizing Biologic Therapy for the Prevention of Post-Operative Recurrence in Crohn's Disease: Current Evidence and Future Perspectives. [europepmc]
• Intact glycoconjugates from Taenia crassiceps excreted/secreted products ameliorate chemically induced colitis by modulating inflammation and strengthening adherens junctions. [europepmc]
• Comparative Safety of Janus Kinase Inhibitors vs Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases. [europepmc]
• Positioning and sequencing of advanced therapies in inflammatory bowel disease: A guide for clinical practice. [europepmc]
• Comparative Safety of JAK Inhibitors vs TNF Antagonists in Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis. [europepmc]
• Ulcerative Colitis: Advances in Pathogenesis, Biomarkers, and Therapeutic Strategies. [europepmc]
• GPR15 differentially regulates the effects of cigarette smoke exposure on Crohn's disease and ulcerative colitis. [europepmc]
• A Comparison of the Efficacy and Safety of Ustekinumab and Upadacitinib in Biologically Experienced Ulcerative Colitis Patients. [europepmc]
• Efficacy and safety of IL-23 inhibitors in the treatment of moderate to severe ulcerative colitis: a meta-analysis based on randomized controlled trials. [europepmc]
• Network meta-analyses in IBD: pitfalls and promise for clinicians. [europepmc]
• MetaMind: A multi-agent transformer-driven framework for automated network meta-analyses. [europepmc]
• Persistence of advanced therapies in patients with ulcerative colitis: real-world data from the nationwide CREdIT registry. [europepmc]
• First Reported Case of Upadacitinib-Associated Cytomegalovirus Viremia and Suspected Pneumonitis in Ulcerative Colitis. [europepmc]
• Interleukin-23 Inhibitors in Inflammatory Bowel Disease. [europepmc]
• From Conventional Therapy to Precision Medicine in Inflammatory Bowel Disease: A State-of-the-Art Review. [europepmc]
• A meta-analysis of the efficacy and safety of Janus kinase inhibitors in patients with ulcerative colitis. [europepmc]
• Outcomes of Difficult-to-Treat Ulcerative Colitis: Impact of Primary Nonresponse vs Secondary Loss of Response to Prior Therapies: A Retrospective Cohort Study. [europepmc]
• Achieving Rapid Remission With Guselkumab in a Moderately Active Ulcerative Colitis Patient With High Infectious Risk and Inadequate Response to Advanced Therapy: A Case Report. [europepmc]
• Kangfuxin liquid enema plus adalimumab for ulcerative colitis: a retrospective cohort study. [europepmc]